Zepbound in Baltimore: How Tirzepatide for Weight Loss Works

Zepbound (tirzepatide) is the FDA-approved injectable for chronic weight management, and it works by activating both GIP and GLP-1 receptors to reduce appetite and slow gastric emptying. For Baltimore patients, eligibility is determined by a licensed clinician who reviews medical history, BMI, and any cardiometabolic conditions before deciding whether the medication is appropriate.

If you're searching for Zepbound in Baltimore, you're likely trying to figure out whether tirzepatide — the dual GIP/GLP-1 receptor agonist Eli Lilly developed for chronic weight management — fits your situation. This piece walks through how the molecule works, what the published trials show, and what questions to bring to a clinician evaluation.

What Zepbound is and how tirzepatide works

Zepbound is the brand name Eli Lilly uses for tirzepatide formulated for chronic weight management. The same active molecule is also marketed for type 2 diabetes under a different brand; the manufacturer secured separate FDA approvals because the indications and dosing pathways differ. Zepbound was approved by the FDA in November 2023 for adults with a BMI of 30 or greater, or a BMI of 27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or established cardiovascular disease.

Mechanistically, tirzepatide is the first dual incretin receptor agonist on the U.S. market. It binds to both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors — two gut hormones the body releases after meals. By engaging both pathways, the molecule slows gastric emptying, blunts post-meal glucose excursions, and dampens appetite signaling in the hypothalamus. The dual-receptor design is what distinguishes it from earlier single-pathway GLP-1 receptor agonists.

What the SURMOUNT trials showed

The pivotal evidence supporting tirzepatide's weight management approval comes from the SURMOUNT clinical trial program. In SURMOUNT-1, a 72-week randomized controlled trial of 2,539 adults with obesity (or overweight with comorbidities) and without diabetes, participants on the 15 mg weekly dose achieved a mean body weight reduction of approximately 22.5%, compared with about 2.4% in the placebo group (Jastreboff et al., NEJM 2022). The 5 mg and 10 mg dose arms also significantly outperformed placebo on body weight and on secondary cardiometabolic endpoints.

SURMOUNT-2 looked at adults with both obesity and type 2 diabetes — a population that historically loses less weight on incretin-based therapies. Over 72 weeks, participants on tirzepatide 15 mg saw mean body weight reductions of roughly 14.7%, versus 3.2% on placebo (Garvey et al., Lancet 2023). The diabetes-population effect size was smaller, but still substantially larger than what was previously achievable with FDA-approved obesity pharmacotherapy.

These outcomes are tied to the studied product — the manufacturer's branded tirzepatide — and to the dosing protocols used in the trials. Real-world results vary based on adherence, comorbidities, baseline weight, and concurrent lifestyle changes.

How clinicians evaluate candidates

A licensed clinician evaluating a Baltimore patient for tirzepatide generally reviews several things before deciding whether to prescribe. BMI and comorbidity profile come first — the FDA labeling requires either BMI ≥30, or BMI ≥27 with at least one weight-related condition. The clinician will also screen for absolute contraindications: a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), and severe gastrointestinal disease such as gastroparesis.

Other history that shapes the decision: a history of pancreatitis, gallbladder disease, severe diabetic retinopathy in patients with type 2 diabetes, and current or planned pregnancy (tirzepatide is not recommended during pregnancy). Patients on oral contraceptives are typically counseled about backup non-oral contraception during titration, since slowed gastric emptying can affect oral medication absorption (FDA Prescribing Information, Zepbound, 2023). Lifestyle factors — diet pattern, physical activity, sleep, and prior weight management attempts — are part of the evaluation because, per the ADA Standards of Care 2024 and major obesity society guidelines, pharmacotherapy is most effective when paired with sustained behavioral change.

If telehealth is more practical than an in-person visit, the Zepbound program at Body Good Men is one route Baltimore patients can use to start that clinical conversation with a US-licensed clinician.

Side effects and safety considerations

The most common adverse events reported in the SURMOUNT trials were gastrointestinal: nausea, diarrhea, vomiting, constipation, and dyspepsia. These tend to be most pronounced during dose escalation and to attenuate over time. Most reports were mild to moderate, but a meaningful subset of participants discontinued therapy due to GI tolerability, particularly during the early titration period.

More serious risks listed in the FDA prescribing information include acute pancreatitis, acute kidney injury (often related to dehydration from severe vomiting or diarrhea), gallbladder disease, hypoglycemia (especially when combined with insulin or sulfonylureas), and a boxed warning regarding thyroid C-cell tumors observed in rodent studies. The human relevance of the rodent finding remains unestablished, but it is the basis for excluding patients with personal or family histories of medullary thyroid carcinoma. Clinicians monitor patients during titration and adjust the plan based on tolerability and response.

The Baltimore context

Maryland has not been spared the national obesity trend. CDC Behavioral Risk Factor Surveillance System data place adult obesity prevalence in Maryland in the low-to-mid 30% range, with rates running higher in Baltimore City than in the surrounding suburban counties. For many Baltimore patients, the structural barriers are less about awareness of treatment options and more about clinician access and insurance coverage. Body Good Men's medically supervised tirzepatide consultation connects eligible patients in Baltimore and the broader Mid-Atlantic with US-licensed clinicians who handle the medical evaluation remotely, with a prescription routed to a partner pharmacy if the clinician determines the patient is a candidate.

It's worth noting that brand-name Zepbound is dispensed by retail and specialty pharmacies; coverage varies considerably by plan. Many commercial insurers in Maryland still classify obesity pharmacotherapy as non-formulary or require step therapy, and Maryland Medicaid coverage for chronic weight management agents has been variable. A clinician evaluation typically includes a discussion of expected coverage and any cash-pay considerations.

What to ask your provider

Useful questions to bring to your visit:

• Based on my BMI, comorbidities, and history, do I meet the FDA labeling criteria for tirzepatide?
• Am I a better candidate for this medication or for a different class of weight management therapy?
• What's the dose-titration plan, and how do you handle GI side effects if they appear?
• How often will we reassess whether the medication is working, and at what threshold do we change course?
• What does my insurance cover, and what are the cash-pay considerations if it isn't covered?
• What lifestyle changes should I commit to alongside the medication for the best long-term outcome?

If you'd like to start that conversation through telehealth, Body Good Men's clinician-led tirzepatide weight management pathway is one option for Baltimore patients.

Frequently asked questions

Is Zepbound the same drug as Mounjaro?

Both medications contain tirzepatide as the active ingredient and are manufactured by Eli Lilly, but the FDA approved them under separate indications: one is approved for chronic weight management in adults with obesity or overweight plus a comorbidity, and the other is approved for type 2 diabetes. The labeling, dosing pathway, and clinical context differ, so a prescribing clinician selects between them based on the diagnosis being treated.

How long does it take to see results with Zepbound?

In the SURMOUNT-1 trial, weight reduction was progressive across 72 weeks, with most participants seeing measurable changes within the first 12 weeks and continued reduction thereafter (Jastreboff et al., NEJM 2022). Individual results vary widely. Clinicians typically reassess after 12 to 16 weeks at a maintenance dose; if a patient hasn't achieved at least a 5% body weight reduction by that point, the treatment plan is usually revisited.

Is Zepbound covered by insurance in Baltimore?

Coverage varies significantly across Maryland insurers. Commercial plans may cover tirzepatide with prior authorization, often requiring documented BMI thresholds and prior weight management attempts. Maryland Medicaid coverage for chronic weight management drugs has been inconsistent. Patients should verify benefits directly with their plan and ask the prescribing clinician about manufacturer savings programs and out-of-pocket considerations if coverage is denied.

What are the most common side effects of Zepbound?

The most common side effects in clinical trials were gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal discomfort — most prominent during dose escalation. The FDA prescribing information also lists rarer but serious risks including pancreatitis, gallbladder disease, kidney injury related to severe dehydration, and a boxed warning regarding thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma should not take tirzepatide.

Can I get Zepbound through telehealth in Baltimore?

Yes. Several telehealth platforms connect Maryland patients with US-licensed clinicians who can evaluate eligibility for FDA-approved tirzepatide and, if appropriate, send the prescription to a participating pharmacy. The patient still needs a documented clinical evaluation — telehealth doesn't bypass the prescribing standards. Coverage, dispensing logistics, and follow-up cadence depend on the platform and on the patient's insurance plan.

Talk to a clinician

If you're considering tirzepatide for chronic weight management and want to know whether it's appropriate for you, talk to a licensed clinician. The Zepbound program at Body Good Men connects you with a US-licensed clinician who reviews your eligibility and, if appropriate, prescribes through our partner pharmacy. Learn more about the Zepbound telehealth pathway through Body Good Men.

---

Important Disclosure

men.joinbodygood.com is operated as an affiliate of Body Good Studio LLC and is a whitelabel certified partner of Leg Up Rx. men.joinbodygood.com does not provide medical services, prescribe medications, or maintain patient records. All clinical evaluations, prescription decisions, and medication fulfillment are handled by licensed medical and pharmacy partners through Leg Up Rx. This article is for general informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any treatment. Eligibility for any medication is determined solely by a licensed clinician.

---